@article{SeefriedMuellerDeubertSchwarzetal.2010, author = {Seefried, Lothar and Mueller-Deubert, Sigrid and Schwarz, Thomas and Lind, Thomas and Mentrup, Birgit and Kober, Melanie and Docheva, Denitsa and Liedert, Astrid and Kassem, Moustapha and Ignatius, Anita and Schieker, Matthias and Claes, Lutz and Wilke, Winfried and Jakob, Franz and Ebert, Regina}, title = {A small scale cell culture system to analyze mechanobiology using reporter gene constructs and polyurethane dishes}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-68099}, year = {2010}, abstract = {Mechanical forces are translated into biochemical signals and contribute to cell differentiation and phenotype maintenance. Mesenchymal stem cells and their tissuespecific offspring, as osteoblasts and chondrocytes, cells of cardiovascular tissues and lung cells are sensitive to mechanical loading but molecules and mechanisms involved have to be unraveled. It is well established that cellular mechanotransduction is mediated e.g. by activation of the transcription factor SP1 and by kinase signaling cascades resulting in the activation of the AP1 complex. To investigate cellular mechanisms involved in mechanotransduction and to analyze substances, which modulate cellular mechanosensitivity reporter gene constructs, which can be transfected into cells of interest might be helpful. Suitable small-scale bioreactor systems and mechanosensitive reporter gene constructs are lacking. To analyze the molecular mechanisms of mechanotransduction and its crosstalk with biochemically induced signal transduction, AP1 and SP1 luciferase reporter gene constructs were cloned and transfected into various cell lines and primary cells. A newly developed bioreactor and small-scale 24-well polyurethane dishes were used to apply cyclic stretching to the transfected cells. 1 Hz cyclic stretching for 30 min in this system resulted in a significant stimulation of AP1 and SP1 mediated luciferase activity compared to unstimulated cells. In summary we describe a small-scale cell culture/bioreactor system capable of analyzing subcellular crosstalk mechanisms in mechanotransduction, mechanosensitivity of primary cells and of screening the activity of putative mechanosensitizers as new targets, e.g. for the treatment of bone loss caused by both disuse and signal transduction related alterations of mechanotransduction.}, subject = {Bioreaktor}, language = {en} } @article{JobsVontheinKoenigetal.2020, author = {Jobs, Alexander and Vonthein, Reinhard and K{\"o}nig, Inke R. and Sch{\"a}fer, Jane and Nauck, Matthias and Haag, Svenja and Fichera, Carlo Federico and Stiermaier, Thomas and Ledwoch, Jakob and Schneider, Alisa and Valentova, Miroslava and von Haehling, Stephan and St{\"o}rk, Stefan and Westermann, Dirk and Lenz, Tobias and Arnold, Natalie and Edelmann, Frank and Seppelt, Philipp and Felix, Stephan and Lutz, Matthias and Hedwig, Felix and Borggrefe, Martin and Scherer, Clemens and Desch, Steffen and Thiele, Holger}, title = {Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA-ADHF-DZHK10 trial}, series = {ESC Heart Failure}, volume = {7}, journal = {ESC Heart Failure}, number = {3}, doi = {10.1002/ehf2.12598}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-212692}, pages = {973 -- 983}, year = {2020}, abstract = {Aims Treating patients with acute decompensated heart failure (ADHF) presenting with volume overload is a common task. However, optimal guidance of decongesting therapy and treatment targets are not well defined. The inferior vena cava (IVC) diameter and its collapsibility can be used to estimate right atrial pressure, which is a measure of right-sided haemodynamic congestion. The CAVA-ADHF-DZHK10 trial is designed to test the hypothesis that ultrasound assessment of the IVC in addition to clinical assessment improves decongestion as compared with clinical assessment alone. Methods and results CAVA-ADHF-DZHK10 is a randomized, controlled, patient-blinded, multicentre, parallel-group trial randomly assigning 388 patients with ADHF to either decongesting therapy guided by ultrasound assessment of the IVC in addition to clinical assessment or clinical assessment alone. IVC ultrasound will be performed daily between baseline and hospital discharge in all patients. However, ultrasound results will only be reported to treating physicians in the intervention group. Treatment target is relief of congestion-related signs and symptoms in both groups with the additional goal to reduce the IVC diameter ≤21 mm and increase IVC collapsibility >50\% in the intervention group. The primary endpoint is change in N-terminal pro-brain natriuretic peptide from baseline to hospital discharge. Secondary endpoints evaluate feasibility, efficacy of decongestion on other scales, and the impact of the intervention on clinical endpoints. Conclusions CAVA-ADHF-DZHK10 will investigate whether IVC ultrasound supplementing clinical assessment improves decongestion in patients admitted for ADHF.}, language = {en} } @phdthesis{Lutz2024, author = {Lutz, Jakob}, title = {Prospektive Validierung des Erlangen Index als pr{\"a}operatives geriatrisches Assessment zur Beurteilung des postoperativen Outcome großer urologischer Eingriffe}, doi = {10.25972/OPUS-35168}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-351686}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2024}, abstract = {Die Gesellschaft altert und es erhalten vermehrt geriatrische Patienten radikale urologische Eingriffe. Alte Patienten haben im Rahmen derartiger Operationen ein erh{\"o}htes Risiko sowohl f{\"u}r Komplikation, verschlechtertes funktionelles Outcome und Mortalit{\"a}t. Da alte Patienten dennoch von den Operationen profitieren k{\"o}nnen und diese auch weitgehend sicher bei diesen durchgef{\"u}hrt werden k{\"o}nnen, gilt es das geriatrische Patientenklientel in Bezug auf ihre Konstitution pr{\"a}operativ genauer zu evaluieren. Die Erlanger Pilotstudie, an die sich vorliegende Arbeit anlehnt, hat dazu einen Index f{\"u}r Patienten ≥ 70 Jahre mit geplanter Prostatektomie, Nephrektomie und Zystektomie entwickelt, der sowohl das postoperative funktionelle Outcome nach 30 bzw. 180 Tagen, wie auch die Mortalit{\"a}t, nicht aber Komplikationen signifikant korrekt vorhersagen konnte. Ziel vorliegender Arbeit war es, die Pr{\"a}diktivit{\"a}t des Erlangen Index hinsichtlich dieser vier Endpunkte in einer prospektiv angelegten Studie mit n=46 Patienten ≥ 65 Jahre am Universit{\"a}tsklinikum W{\"u}rzburg zu validieren. Es sollte dabei im Speziellen die in der Erlanger Pilotstudie erfasste gute Pr{\"a}diktivit{\"a}t des Erlangen Index f{\"u}r das funktionelle Outcome nach 180 Tagen {\"u}berpr{\"u}ft werden. In dieser Arbeit zeigte sich der Erlangen Index pr{\"a}diktiv f{\"u}r das funktionelle Outcome nach 180 Tagen. F{\"u}r die anderen Endpunkte konnte keine Pr{\"a}diktivit{\"a}t des Erlangen Index festgestellt werden. Durch vorliegende Studie konnte die schlechte Pr{\"a}diktion der Komplikationen durch den EI best{\"a}tigt werden. Anders als in der Pilotstudie war der Erlangen Index in vorliegender Studie zur Vorhersage des funktionellen Outcome nach 30 Tagen und der Mortalit{\"a}t nicht geeignet. Bei Betrachtung der Untergruppen nach Art der Operation zeigte der EI starke Korrelationen f{\"u}r die Pr{\"a}diktion des funktionellen Outcome nach 180 Tagen in den Gruppen der Patienten nach Prostata- und Harnblasenoperation. Die Ergebnisse decken sich somit nur teilweise mit den Ergebnissen aus der Pilotstudie in Erlangen, in der der Erlangen Index bzgl. des funktionellen Outcome nach 180 Tagen die gr{\"o}ßte Korrelation in der Untergruppe der Patienten nach Nephrektomie zeigte. Der Index erwies sich als schnell durchf{\"u}hrbares Assessment, das wenig Personal erfordert. Es ist weiter zu pr{\"u}fen, ob sich durch Anwendung dieses Assessment tats{\"a}chlich {\"A}nderungen im klinischen Therapieregime ergeben bzw. ob sich die Modifizierungen der Therapie auch in einem verbesserten Outcome der Patienten auswirken.}, subject = {Operation}, language = {de} }